Menu
NASP

All Activities

Find an Activity

Find an Activity

Find an Activity

Choose from the criteria below to find an activity that fits you best.

Attention Pharmacists and Pharmacy Techs: Click to access CPE Monitor and latest CE information More Information

Featured Activity

This activity will cover key topics of interest to stakeholders who set practice policy and will be called upon to evaluate and make decisions on issues pertaining to biosimilars.

Find an Activity

Find an Activity

Find an Activity

Choose from the criteria below to find an activity that fits you best.

SHOW SEARCH

An Overview of Biosimilars: Potential Implications for Pharmacists

Activity Downloads

To Participate

To participate in this continuing education activity:

  1. Review the activity description and objectives.
  2. View the activity.
  3. Complete the online post-test and activity evaluation.
A product of the National Association of Specialty Pharmacy's (NASP) Center for Specialty Pharmacy Education (CSPE) 

 
 View more NASP/CSPE Activities
 

Activity Description

This is a featured CE activity on the Center for Specialty Pharmacy Education (CSPE) website. CSPE is the educational hub of the National Association of Specialty Pharmacy (NASP). Most CSPE activities include the pathophysiology and clinical therapeutics of various disease states in which specialty pharmacy products and services are provided. CSPE also covers legal, regulatory and operational topics relevant to specialty pharmacy practice.

Learning Objectives

The target audience for this activity is pharmacists. Upon completion of this activity, participants will be able to:

  • Outline the differences between biopharmaceuticals, biosimilars, and generic medications
  • Describe the potential impact that changes in manufacturing and sourcing of ingredients for biosimilar products may have on immunogenicity,safety, and efficacy
  • Discuss the critical issues of naming, interchangeability, and pharmacovigilence with biosimilar products including biopharmaceuticals with a narrow therapeutic window such as insulin
  • Describe potential issues for formulary review in P&T

Faculty

Ali McBride, PharmD, MS BCPS, BCOP
Clinical Coordinator Hematology/Oncology
Department of Pharmacy
The University of Arizona Cancer Center

Disclosure

It is the policy of ProCE, Inc. to ensure balance, independence, objectivity and scientific rigor in all of its continuing education activities. Faculty must disclose to participants any significant financial interest or affiliation with companies that manufacture or market products discussed during their presentation. Dr. McBride has served as a consultant/speaker for Amgen and Hospira.

The opinions expressed in this activity should not be construed as those of the CE provider. The information and views are those of the faculty through clinical practice and knowledge of the professional literature. Portions of this activity may include the use of drugs for unlabeled indications. Use of drugs outside of labeling should be considered experimental and participants are advised to consult prescribing information and professional literature.

CE Accreditation

Release Date: 09-1-2015
Expiration Date: 09-1-2018

Pharmacists

This CE activity is jointly provided by ProCE, Inc. and NASP. ProCE is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-9999-15-227-H04-P has been assigned to this knowledge-based home-study CE activity (initial release date 09-01-15). This activity is approved for 1.0 contact hour (0.1 CEU) in states that recognize ACPE providers. Completion of the evaluation and the post-test with a score of 70% or higher are required to receive CE credit. No partial credit will be given.

Funding

No external support has been received for this activity.

 

The material presented in this CE activity does not reflect the views of ProCE, Inc. or the commercial sponsor. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.